Current Search:  Blanks, Janet (x)

View All Items

  • CSV Spreadsheet
(1 - 7 of 7)
GFAP-based gene therapy for treatment of retinal diseases
Title
GFAP-based gene therapy for treatment of retinal diseases.
Creator
Dorey, C. Kathleen, Blanks, Janet C., Prentice, Howard, Florida Atlantic University
Date Issued
2005-11
PURL
http://purl.flvc.org/fcla/dt/15800
Format
Document (PDF)
The NSAID, Sulindac confers protection against oxidative stress induced damage in retinal pigmented epithelial cells
Title
The NSAID, Sulindac confers protection against oxidative stress induced damage in retinal pigmented epithelial cells.
Creator
Sur, Arunodoy, Biswal, Manas, Kreymerman, Alexander, Weissbach, Herbert, Prentice, Howard, Blanks, Janet C., Graduate College
Date Issued
2011-04-08
PURL
http://purl.flvc.org/fcla/dt/3164798
Subject Headings
Nonsteroidal anti-inflammatory agents, Oxidative stress, Epithelial cells
Format
Document (PDF)
Interleukin 10 (IL-10) selectively inhibits neovascularization in the Murine model of Retinopathy of Prematurity
Title
Interleukin 10 (IL-10) selectively inhibits neovascularization in the Murine model of Retinopathy of Prematurity.
Creator
Solomon, Evertz Stenson, Blanks, Janet C., Florida Atlantic University
Abstract/Description
Ocular neovascularization (NV), the development of new blood vessels in the eye, occurs when excessive vascular endothelial growth factor (VEGF) is produced. Eventually NV may lead to photoreceptor loss and or blindness, as it does in age-related macular degeneration (AMD), retinopathy of prematurity (ROP), and diabetic retinopathy. We tested the hypothesis that the anti-inflammatory cytokine, interleukin-10 (IL-10); can reduce inflammation and block NV in the affected areas of the retina....
Show moreOcular neovascularization (NV), the development of new blood vessels in the eye, occurs when excessive vascular endothelial growth factor (VEGF) is produced. Eventually NV may lead to photoreceptor loss and or blindness, as it does in age-related macular degeneration (AMD), retinopathy of prematurity (ROP), and diabetic retinopathy. We tested the hypothesis that the anti-inflammatory cytokine, interleukin-10 (IL-10); can reduce inflammation and block NV in the affected areas of the retina. The mouse ROP model was used for this study of NV. Seven day old neonates stayed in 75% oxygen for five days, then were given intraocular injection of IL-100 and NV was evaluated after seven days in room air. Controls were uninjected contralateral eyes. IL-l 0 strongly inhibited NV without affecting intra-retinal vessels. The selective inhibition of IL-10 on NV suggest a possible therapeutic use in infants with ROP, in diabetic retinopathy, and possibly, in AMD where inflammation is a risk factor.
Show less
Date Issued
2007
PURL
http://purl.flvc.org/fau/fd/FA00000833
Subject Headings
Neovascularization, Neovascularization inhibitors, Interleukin-10
Format
Document (PDF)
Materials and Methods for the Treatment of Pathological Neovascularization in the Eye, 2012
Title
Materials and Methods for the Treatment of Pathological Neovascularization in the Eye, 2012.
Creator
Blanks, Janet C., Prentice, Howard M., Florida Atlantic University, Dorey, C. Kathleen
Abstract/Description
The subject invention provides materials and methods useful in safely and effectively preventing pathological proliferation of blood vessels. The prevention of the over-proliferation of blood vessels according to the subject invention is particularly advantageous for treatment of certain ocular conditions including age-related macular degeneration (AMD), retinopathy of prematurity (ROP) and diabetic retinopathy. In preferred embodiments, the subject invention provides materials and methods...
Show moreThe subject invention provides materials and methods useful in safely and effectively preventing pathological proliferation of blood vessels. The prevention of the over-proliferation of blood vessels according to the subject invention is particularly advantageous for treatment of certain ocular conditions including age-related macular degeneration (AMD), retinopathy of prematurity (ROP) and diabetic retinopathy. In preferred embodiments, the subject invention provides materials and methods for effective treatment of pathological ocular neovascularization using gene therapy. In a specific embodiment the materials and methods of the subject invention can be used to treat AMD.
Show less
Date Issued
2012
PURL
http://purl.flvc.org/fau/fd/FAUIR000245
Format
Document (PDF)
GFAP-Based Gene Therapy for Treatment of Retinal Diseases, 2008
Title
GFAP-Based Gene Therapy for Treatment of Retinal Diseases, 2008.
Creator
Dorey, C. Kathleen, Blanks, Janet C., Florida Atlantic University, Prentice, Howard
Abstract/Description
Compositions and methods for reducing neovascularization. Purified nucleic acid constructs and vectors encoding an antiangiogenic protein operably linked to a GFAP promoter. Vectors can include at least one hypoxia regulated element, enhancer element and silencer element. Gene therapy methods for reducing, delaying or preventing neovascularization based on the nucleic acid constructs and vectors.
Date Issued
2008
PURL
http://purl.flvc.org/fau/fd/FAUIR000259
Format
Document (PDF)
Differential effect of sulindac on normal and malignant retinal cells
Title
Differential effect of sulindac on normal and malignant retinal cells.
Creator
Sur, Arunodoy, Blanks, Janet C., Charles E. Schmidt College of Science, Center for Complex Systems and Brain Sciences
Abstract/Description
Age related macular degeneration (AMD) is the leading cause of blindness among the elderly population and oxidative stress induced damage of ocular tissues is thought to play an important role in the etiology of this disease. This current study is aimed at testing pharmacological preconditioning as a possible protective mechanism for retinal cells against oxidative stress induced damage. Since the retinal pigment epithelial (RPE) cells located adjacent to the photoreceptor cells, are believed...
Show moreAge related macular degeneration (AMD) is the leading cause of blindness among the elderly population and oxidative stress induced damage of ocular tissues is thought to play an important role in the etiology of this disease. This current study is aimed at testing pharmacological preconditioning as a possible protective mechanism for retinal cells against oxidative stress induced damage. Since the retinal pigment epithelial (RPE) cells located adjacent to the photoreceptor cells, are believed to be responsible for the initial pathology in AMD we tested our therapy on this cell type. Earlier research conducted with lung cells and in a cardiac model with the nonsteroidal anti-inflammatory drug (NSAID) sulindac (Moench et al., 2009; Marchetti et al., 2009) indicate that sulindac can protect normal cells from oxidative damage through ischemic preconditioning (IPC) pathways. This led us to test whether sulindac can also protect significant protection against both tert-butyl hydrogen peroxide (TBHP) induced chemical stress and UVB light induced photooxidative damage through a preconditioning mechanism.
Show less
Date Issued
2013
PURL
http://purl.flvc.org/fau/fd/FA00004258
Format
Document (PDF)
Pharmacological protection of retinal pigmented epithelial cells by sulindac involves PPAR-α
Title
Pharmacological protection of retinal pigmented epithelial cells by sulindac involves PPAR-α.
Creator
Sur, Arunodoy, Kesaraju, Shailaja, Prentice, Howard, Ayyanathan, Kasirajan, Baronas-Lowell, Diane, Zhu, Danhong, Hinton, David R., Blanks, Janet, Weissbach, Herbert
Date Issued
2014-11-10
PURL
http://purl.flvc.org/fau/flvc_fau_islandoraimporter_10.1073_pnas.1419576111_1631807081
Format
Citation